Avanos Medical, Inc. (AVNS)
NYSE: AVNS · Real-Time Price · USD
16.08
-0.46 (-2.78%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.

It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.

The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems.

In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx’s knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions.

It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors.

The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018.

Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Avanos Medical, Inc.
Avanos Medical logo
Country United States
Founded 2014
Industry Medical Devices
Sector Healthcare
Employees 3,771
CEO Michael Greiner

Contact Details

Address:
5405 Windward Parkway, Suite 100 South
Alpharetta, Georgia 30004
United States
Phone 844 428 2667
Website avanos.com

Stock Details

Ticker Symbol AVNS
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001606498
CUSIP Number 05350V106
ISIN Number US05350V1061
Employer ID 46-4987888
SIC Code 3842

Key Executives

Name Position
Mojirade James Senior Vice President, General Counsel and Corporate Secretary
Kerr W. Holbrook Senior Vice President and Chief Commercial Officer
Warren J. Machan Interim Chief Financial Officer
John Joseph Hurley Principal Accounting Officer and Controller
David Crawford Vice President of FP&A and Investor Relations and Treasurer
Michelle Scharfenberg Senior Vice President and Chief Ethics and Compliance Officer
Scott Galovan Vice President of Strategy and Corporate Development
John W. Cato Vice President of Human Resources
Lee Burnes Senior Vice President of Global Research & Development, Clinical and Medical Affairs
Sigfrido Delgado Senior Vice President of Integrated Supply Chain

Latest SEC Filings

Date Type Title
Dec 3, 2024 8-K Current Report
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 8-K Current Report
Oct 30, 2024 10-Q Quarterly Report
Oct 30, 2024 8-K Current Report
Jul 31, 2024 10-Q Quarterly Report
Jul 31, 2024 8-K Current Report
Jul 3, 2024 3 Initial statement of beneficial ownership of securities
Jul 1, 2024 8-K Current Report
May 28, 2024 SD Form - SD